Key points are not available for this paper at this time.
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway.
Müller et al. (Wed,) studied this question.